XiMo and Aspira Scientific Launch Air-Stable Metathesis Pills
XiMo AG and Aspira Scientific, Inc. (Milpitas, California) announced the launch of air-stable catalyst pills (CatPac’s) for metathesis chemistry. These catalysts represent exceptional value to the chemical industry, especially in pharmaceutical development, given the low cost of Mo compared to ruthenium (Ru) (100-fold less expensive), and its high body tolerance (non-toxic as opposed to Ru). These highly active catalysts are made to be more convenient to use for rapid screening by formulating them in an air-stable pill format.
Ximo provides highly selective olefin metathesis catalysts that enable synthetic efficiency.
For example, research at XiMo laboratories indicates that catalyst to substrate ratios of at least 1 to 10,000 can be achieved in a cross-metathesis reaction.
XiMo partners with selected leading companies, providing access to its intellectual property and technical expertise, to solve important industrial chemistry problems.
XiMo was founded in 2010 by MIT and Nobel price winner Professor Richard Schrock and Boston College Professor Amir Hoveyda, along with a small group of other investors and co-founders.